in-PharmaTechnologist.com presents its round-up of the latest pharmaceutical industry appointments, including news from Okairos, Immunovaccine, and SteadyMed.
T-cell vaccine specialist Okairos has two new board members in Bill Burns and Jean-Paul Prieels. Burns, previously CEO of Roche's pharmaceuticals division, is now chairman of the board. Former head of research at GSK Vaccines Prieels completes the expansion. The company has also hired new chief operating officer Tom Woiwode.
Immunovaccine has announced the appointment of John Trizzino as their new CEO. Trizzino, a former senior VP at Novavax, has focussed his 25 year career on vaccine development.
"As our development program accelerates with a second cancer vaccine in the clinic, we are pleased to be joined by someone with John's experience in partnering, licensing and distribution," said Albert Scardino, Chairman of Immunovaccine.
Jonathan Rigby has been named as president and CEO at SteadyMed Therapeutics. He succeeds Yossi Aldar, who has been at the helm of the business since its inception.
Of his replacement, Alder said: “I am delighted to welcome Jonathan at this pivotal time as we advance towards our goal of becoming a commercially focused drug delivery therapeutics company.
“Jonathan's deep appreciation for both the critical elements required to execute on our strategy, as well as a proven track record in the financing and commercialization of drug delivery enabled products will be a great asset. I look forward to Jonathan's leadership at this exciting time for SteadyMed."
Scott Myers has taken the role of president and CEO at Aerocrine as part of the company’s new strategy to focus on the reimbursement and commercialisation of products. He joins Aerocrine from UCB where he most recently held the position of VP, head of European mid-markets.
Anders Williamsson, chairman of the board, said: “Aerocrine’s Board and management have worked purposefully to establish the company’s US operations and commercial organization.”
The US is the world’s largest market for Aerocrine’s products and we expect that market conditions in the US will continue to develop favourably. Scott's appointment is a natural and important step in the company’s long term strategy and we are delighted to welcome Scott to Aerocrine.
Cambridge UK-based Team Consulting has appointed David Harris as principle consultant. The firm is currently developing several new medical devices in pulmonary and nasal drug delivery. In his new role Harris will oversee this section of the business.